<DOC>
	<DOC>NCT00215566</DOC>
	<brief_summary>This study will evaluate the safety, tolerability and pharmacodynamics of the investigational drug DDP733 in treating subjects with IBS-c. A placebo control will be utilized.</brief_summary>
	<brief_title>A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of DDP733 for IBS-c</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Subjects must have a history of IBSc for at least 3 months prior to randomization as assessed using ROME criteria Must have had endoscopic/radiologic bowel evaluation within the past 10 years Must comply with completing a daily diary and be able to comply with GI transit measurements, including swallowing capsules containing small xray visible markers Female subjects cannot be pregnant, postpartum for less than 1 year or breastfeeding Serious underlying diseases, including psychiatric disorders Current history of conditions affecting bowel transit Recent history of biochemical or structural abnormalities of the gastrointestinal tract, gastrointestinal surgery, or gastrointestinal infection Clinically significant abnormal examination findings or laboratory tests Inability to stop taking certain medications, or a planned change in medications (including herbal remedies) which could interfere with study assessments Use of drugs and or ethanol which may interfere with compliance of study procedures or influence study outcome Presence of a medical condition which could interfere with the interpretation of study data Significant use of nicotine or caffeine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2006</verification_date>
	<keyword>IBS</keyword>
	<keyword>IBS-c</keyword>
</DOC>